Document Detail


Growth factor therapy for vocal fold scarring in a canine model.
MedLine Citation:
PMID:  15535139     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Vocal fold scarring remains a therapeutic challenge. Hepatocyte growth factor (HGF) has strong antifibrotic activity and has proved to have therapeutic potential in restoration of scar tissues such as liver cirrhosis and lung fibrosis. The present study aimed to clarify the effects of HGF injection into scarred vocal folds in a canine model. Canine vocal folds were stripped unilaterally and treated with intracordal injection of saline solution (sham group), HGF (HGF group), or HGF with cultured autologous normal vocal fold fibroblasts (Fb/HGF group) 1 month after injury. The larynges were harvested 6 months after the initial injury and then subjected to vibratory and histologic examination. The results of vibratory examinations in the excised larynx setup revealed that phonation threshold pressure significantly increased and vocal efficiency was significantly reduced in all treated groups as compared to normal data obtained from normal canine larynges. However, the HGF group presented much better results than both the sham and Fb/HGF groups in terms of mucosal wave amplitude and incidence of vocal fold bowing, glottal incompetence, and phase asymmetry. The histologic data indicated a significant increase of collagen in both the sham and Fb/HGF groups, while normal levels of collagen were found in the HGF group. Tissue contraction of the lamina propria was also observed in both the sham and Fb/HGF groups, but was barely detectable in the HGF group. Although the HGF-treated vocal folds appeared to require more driving forces for vibration, HGF might prevent excessive collagen deposition and tissue contraction and thus reduce the effects of scarring on the vibratory properties of the vocal folds. From these data it is concluded that HGF has considerable potential in the treatment of vocal fold scarring.
Authors:
Shigeru Hirano; Diane M Bless; Hiromi Nagai; Bernard Rousseau; Nathan V Welham; Douglas W Montequin; Charles N Ford
Related Documents :
25068429 - Cardiopulmonary exercise testing prior to myeloablative allo-sct: a feasibility study.
11200989 - Can daily centrifugation prevent the haematocrit increase elicited by 6-degree, head-do...
11973849 - Cardiovascular studies during and following simulation and weightlessness.
23713529 - Cardiovascular drift in trained paraplegic and able-bodied individuals during prolonged...
2295379 - Morphological and biochemical examination of cosmos 1887 rat heart tissue: part i--ultr...
11356789 - Midodrine prevents orthostatic intolerance associated with simulated spaceflight.
9617729 - The relationship between open and closed kinetic chain strength of the lower limb and j...
6136959 - A comparison of nifedipine and isosorbide dinitrate in angina pectoris with particular ...
10680659 - Comparative cardiopulmonary effects of carfentanil-xylazine and medetomidine-ketamine u...
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  The Annals of otology, rhinology, and laryngology     Volume:  113     ISSN:  0003-4894     ISO Abbreviation:  Ann. Otol. Rhinol. Laryngol.     Publication Date:  2004 Oct 
Date Detail:
Created Date:  2004-11-10     Completed Date:  2004-12-02     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  0407300     Medline TA:  Ann Otol Rhinol Laryngol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  777-85     Citation Subset:  AIM; IM    
Affiliation:
Department of Surgery, Division of Otolaryngology-Head and Neck Surgery, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Disease Models, Animal
Dogs
Hepatocyte Growth Factor / therapeutic use*
Image Processing, Computer-Assisted
Male
Vibration
Vocal Cords / pathology*
Grant Support
ID/Acronym/Agency:
R01 DC4428/DC/NIDCD NIH HHS
Chemical
Reg. No./Substance:
67256-21-7/Hepatocyte Growth Factor

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Functional outcomes of reduced hyaluronan in acute vocal fold scar.
Next Document:  Tracheal and laryngeal rupture in neonates: complication of delivery or of intubation?